focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Regulatory News (ZTF)

Share Price Information for Zotefoams (ZTF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 528.00
Bid: 520.00
Ask: 530.00
Change: 8.00 (1.54%)
Spread: 10.00 (1.923%)
Open: 524.00
High: 528.00
Low: 524.00
Prev. Close: 520.00
ZTF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

2022 Annual Report and Notice of the 2023 AGM

21 Apr 2023 07:00

RNS Number : 9778W
Zotefoams PLC
21 April 2023
 

Zotefoams plc

(the 'Company' or the 'Group')

 

 

2022 Annual Report and Notice of the 2023 Annual General Meeting

 

21 April 2023 - The Company has published its 2022 Annual Report and the Notice of the 2023 Annual General Meeting to be held at 675 Mitcham Road, Croydon CR9 3AL on 24 May 2023 at 10.00 a.m. on:

https://www.zotefoams.com/investors/annual-interim-reports/

https://www.zotefoams.com/investors/agm/

 

In compliance with Listing Rule 9.6.1, the following documents have been submitted to the National Storage Mechanism and will shortly be available for inspection at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

1. Annual Report for the year ended 31 December 2022 prepared using the single electronic reporting format specified in the TD ESEF Regulation, incorporating the Notice of the 2023 Annual General Meeting; and

 

2. Form of Proxy for the 2023 Annual General Meeting.

 

A condensed set of the financial statements, the Chair's introduction, the Group CEO's review and the Group CFO's review in respect of the Annual Report were included in the unaudited preliminary results announcement issued on 21 March 2023, which may be found at:

www.zotefoams.com/investors/announcements/ 

 

This announcement contains, in Annex A, additional information for the purposes of compliance with the Disclosure, Guidance and Transparency Rules, including the statement of Directors' responsibilities in respect of the financial statements, a description relating to principal risks and uncertainties, and details of related party transactions. This information is extracted from the 2022 Annual Report. This announcement is not a substitute for reading the full Annual Report. Page and note references in the text below refer to page numbers and notes in the 2022 Annual Report.

 

A presentation open to all existing and potential shareholders will be given after the AGM on 24 May 2023 at 1.30pm on the Investor Meet Company platform:

www.investormeetcompany.com/register-investor. Investors who already follow Zotefoams plc on the Investor Meet Company platform will automatically be invited.

 

Enquiries:

 

Lydia Harratt

Group Company Secretary

Zotefoams plc

020 8664 1600

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA, Stilling, Denmark (microcellular foam technology) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

 

Annex A

 

 

Statement of Directors' responsibilities in respect of the financial statements

The Directors consider the Annual Report, taken as a whole, to be fair, balanced and understandable.

The Directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulation.

Company law requires the Directors to prepare financial statements for each financial year. Under that law, the Directors have prepared the Group and Company financial statements in accordance with UK-adopted international accounting standards. Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and Company and of the profit or loss of the Group and Company for that period. In preparing the financial statements, the Directors are required to:

• Select suitable accounting policies and then apply them consistently

• State whether applicable UK-adopted international accounting standards have been followed subject to any material departures disclosed and explained in the financial statements

• Make judgements and accounting estimates that are reasonable and prudent and

• Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group and Company will continue in business.

The Directors are also responsible for safeguarding the assets of the Group and Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Group's and Company's transactions and disclose with reasonable accuracy at any time the financial position of the Group and Company and enable them to ensure that the financial statements and the Directors' Remuneration report comply with the Companies Act 2006.

The Directors are responsible for the maintenance and integrity of the Company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The Directors consider that the Annual Report, taken as a whole, is fair, balanced and understandable and provides the information necessary for shareholders to assess the position and performance, business model and strategy of the Group and Company.

Each of the Directors, whose names and functions are listed on pages 78 and 79 of the Annual Report, confirm that, to the best of their knowledge:

• The Consolidated and Company financial statements, which have been prepared in accordance with UK-adopted international accounting standards, give a true and fair view of the assets, liabilities, financial position and profit of the Group and Company and

• The Group CEO's review includes a fair review of the development and performance of the business and the position of the Group and Company. A description of the principal risks and uncertainties faced by the Group and the Company is provided on pages 41 to 50.

 

 

Principal risks and uncertainties

The Group is exposed to a wide range of risks in addition to those listed, and these are managed through the risk management framework shown on page 40. This framework enables us to monitor for any increase in likelihood or impact and ensure that we have the appropriate mitigations in place. The details of our principal risks and uncertainties and the key mitigating activities can be found on pages 41 to 50. We are disclosing those risks and uncertainties that we believe have the greatest impact in achieving our strategic objectives.

Zotefoams' risk profile will evolve as the business grows at its targeted pace, although we expect these principal risks and uncertainties to remain broadly consistent.

 

 

Related party transactions

 

Directors

The Directors of the Company as at 31 December 2022 and their immediate relatives control approximately 1.3% (2021: 1.2%) of the voting shares of the Company. Details of Directors' pay and remuneration are given in the Directors' Remuneration report on pages 88 to 109. Executive Directors are considered to be the only key management personnel. Details of compensation paid to key management personnel are included in note 5.

 

Subsidiaries and joint venture

Details of the joint venture and subsidiaries of the Company are set out in notes 9 and 13. These companies are considered to be related parties.

 

The following material transactions were carried out with related parties:

2022£'000

2021£'000

Sale of goods: subsidiaries of the Company

3,875

3,857

Sale of services: subsidiaries of the Company

2,537

1,246

Loans given (net of repayments): subsidiaries of the Company

(2,419)

2,748

Interest income: subsidiaries of the Company

657

468

Sale of goods: joint venture of the Company

3,444

2,951

Sale of services: joint venture of the Company

232

733

Total

8,326

12,003

 

 

 

 

 

 

 

Balances between the Company and its active subsidiaries and joint venture are as follows:

Receivable from/(payable to)

Investment in

2022£'000

2021£'000

2022£'000

2021£'000

Zotefoams Inc.

13,163

12,541

-

-

KZ Trading and Investment Limited

-

247

-

-

Azote Asia Limited

1,304

1,065

-

-

MuCell Extrusion LLC

6,511

4,410

-

-

Zotefoams International Limited

16,370

17,037

30,822

30,822

Zotefoams T-FIT Material Technology (Kunshan) Limited

3,438

2,993

-

-

Zotefoams Poland Sp. z.o.o.

291

304

-

-

Zotefoams France SAS

(59)

(39)

-

-

T-FIT Insulation Solutions India Private Limited

75

253

-

-

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAPPUMGCUPWGMU
Date   Source Headline
3rd Dec 20153:30 pmRNSHolding(s) in Company
1st Dec 201511:54 amRNSHolding(s) in Company
30th Nov 20159:59 amRNSTotal Voting Rights
25th Nov 20151:28 pmRNSApplication for the listing of shares
24th Nov 20157:00 amRNSAppointment of Finance Director Designate
2nd Nov 20157:00 amRNSThird Quarter Trading Update
2nd Oct 20154:45 pmRNSHolding(s) in Company
2nd Oct 20159:06 amRNSHolding(s) in Company
8th Sep 20153:56 pmRNSDirector/PDMR Shareholding
7th Aug 20159:00 amRNSDirector/PDMR Shareholding
4th Aug 20157:00 amRNSHalf Yearly Report
10th Jul 20157:00 amRNSTrading Update
9th Jul 201511:38 amRNSHolding(s) in Company
2nd Jul 20157:30 amRNSDirector Declaration
23rd Jun 20154:08 pmRNSHolding(s) in Company
22nd Jun 20154:58 pmRNSHolding(s) in Company
22nd Jun 20152:39 pmRNSHolding(s) in Company
27th May 20158:57 amRNSHolding(s) in Company
13th May 20153:00 pmRNSResult of AGM
13th May 20157:00 amRNSAGM Trading Update
13th Apr 20153:22 pmRNSDirector/PDMR Shareholding
10th Apr 20159:30 amRNSAnnual Report and Notice of AGM
31st Mar 20159:26 amRNSDirector/PDMR Shareholding
30th Mar 201510:55 amRNSHolding(s) in Company
27th Mar 20153:32 pmRNSHolding(s) in Company
23rd Mar 20158:40 amRNSHolding(s) in Company
17th Mar 20157:00 amRNSFinal Results
11th Mar 20153:51 pmRNSNew venture with China-based King Lai Group
16th Jan 20154:18 pmRNSNotification of Major Interest in Shares
9th Jan 20158:47 amRNSHolding(s) in Company
7th Jan 20157:00 amRNSTrading Update
7th Nov 20147:00 amRNSInterim Management Statement
20th Oct 20147:01 amRNSDirector Declaration
6th Oct 20142:07 pmRNSDirector/PDMR Shareholding
25th Sep 20147:00 amRNSAppointments of Non-executive Directors
19th Sep 201410:31 amRNSHolding(s) in Company
19th Sep 201410:30 amRNSHolding(s) in Company
17th Sep 20149:45 amRNSDirector/PDMR Shareholding
17th Sep 20149:41 amRNSTotal Voting Rights
16th Sep 20144:45 pmRNSHolding(s) in Company
12th Sep 20147:00 amRNSPlacing to raise approximately £8.8m
12th Aug 20147:00 amRNSHalf Yearly Report
29th Jul 201411:17 amRNSHolding(s) in Company
30th Jun 20147:00 amRNSTrading Statement
20th May 201412:59 pmRNSResult of AGM
19th May 20147:00 amRNSAGM Statement and Interim Management Statement
13th May 20143:31 pmRNSDirectorate Change
22nd Apr 201412:41 pmRNSUnilever to use MuCell technology for Dove bottles
14th Apr 20144:04 pmRNS2013 Annual Report & Accounts and Notice of AGM
9th Apr 20149:06 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.